Published • loading... • Updated
US Cancer Clinics Scramble to Get Experimental Revolution Medicines Pancreatic Cancer Drug
Cancer centers are enrolling patients early as Revolution Medicines seeks faster FDA approval for its pancreatic cancer drug, which showed a 57% survival rate in a trial.
- Cancer centers are scrambling to enroll patients in an expanded access program for daraxonrasib, a pancreatic cancer drug from Revolution Medicines, following a surge in patient requests.
- The drug targets a genetic mutation found in approximately 90 percent of pancreatic cancers, extending median survival to 13.2 months compared to 6.7 months with standard chemotherapy.
- "Patients are already aware of the press release and are already calling," said Dr. Vincent Chung of City of Hope, while oncologists at Zuckerberg Cancer Center work to provide access.
- Dr. Chung expressed concern about potential volume, stating, "I'm sure they don't want to have 10,000 applications at once," as oncologists urge the Food and Drug Administration to establish streamlined enrollment protocols.
- Revolution Medicines CEO Mark Goldsmith affirmed there is a "full-throttle effort" to provide access, while daraxonrasib remains in the Food and Drug Administration's expedited review process from last year.
Insights by Ground AI
32 Articles
32 Articles
Cancer Centers Rush for New Pancreatic Cancer Drug Trial
U.S. cancer centers are racing to enroll patients in an early access program for a promising pancreatic cancer drug from Revolution Medicines while awaiting FDA approval. The drug, daraxonrasib, has shown potential to double survival rates in patients with advanced pancreatic cancer, prompting widespread interest and challenges in program implementation.
·India
Read Full Article
Coverage Details
Total News Sources32
Leaning Left2Leaning Right1Center28Last UpdatedBias Distribution90% Center
Bias Distribution
- 90% of the sources are Center
90% Center
C 90%
Factuality
To view factuality data please Upgrade to Premium
